Translocator protein explained

Translocator protein (TSPO) is an 18 kDa protein mainly found on the outer mitochondrial membrane.[1] It was first described as peripheral benzodiazepine receptor (PBR), a secondary binding site for diazepam, but subsequent research has found the receptor to be expressed throughout the body and brain.[2] In humans, the translocator protein is encoded by the TSPO gene.[3] [4] It belongs to a family of tryptophan-rich sensory proteins. Regarding intramitochondrial cholesterol transport, TSPO has been proposed to interact with StAR (steroidogenic acute regulatory protein) to transport cholesterol into mitochondria, though evidence is mixed.[5]

Function

In animals, TSPO (PBR) is a mitochondrial protein usually located in the outer mitochondrial membrane and characterised by its ability to bind a variety of benzodiazepine-like drugs, as well as to dicarboxylic tetrapyrrole intermediates of the haem biosynthetic pathway.

TSPO has many proposed functions depending on the tissue.[6] The most studied of these include roles in the immune response, steroid synthesis and apoptosis.

Cholesterol transport and bile acid biosynthesis

Mitochondrial cholesterol transport is a molecular function closely tied to TSPO in the scientific literature. TSPO binds with high affinity to the lipid cholesterol, and pharmacological ligands of TSPO facilitate cholesterol transport across the mitochondrial intermembrane space to stimulate steroid synthesis and bile acid synthesis in relevant tissues.[7] However, TSPO deletion in genetically engineered mouse models has yielded mixed results regarding the physiological necessity of TSPO's role in steroidogenesis. Deletion of TSPO in steroidogenic Leydig cells did not impair synthesis of the steroid testosterone.[8] Thus, though biochemical and pharmacological experimentation suggest an important role for TSPO in cellular cholesterol transport and steroid biosynthesis,[9] TSPO's necessity in this process remains controversial.

Regulation in the heart

TSPO (Translocator protein) acts to regulate heart rate and contractile force by its interaction with voltage-dependent calcium channels in cardiac myocytes.[10] The interaction between TSPO and calcium channels can alter cardiac action potential durations, thus contractility of the heart. In healthy individuals, TSPO has a cardio-protective role. When TSPO is up-regulated in the presence of infections, it can limit the inflammatory response, which can be cardio-damaging.[11]

Immunomodulation

PBRs (TSPOs) have many actions on immune cells including modulation of oxidative bursts by neutrophils and macrophages, inhibition of the proliferation of lymphoid cells and secretion of cytokines by macrophages.[12] [13] Expression of TSPO is also linked to inflammatory responses that occur after ischemia-reperfusion injury, following hemorrhagic brain injury,[14] and in some neurodegenerative diseases.

Increased expression of TSPO is linked to the inflammatory responses in the heart that may cause myocarditis, which can lead to myocardial necrosis. TSPO is present in mast cells and macrophages, indicating its role in the immune system.[10] Oxidative stress is a strong contributing factor to cardiovascular disease, and often occurs because of inflammation caused by ischemia reperfusion injury.[15] Coxsackievirus B3 (CVB3) causes immune cells CD11b+ (present on macrophages) to stimulate inflammatory infiltration. Functionally, CD11b+ regulates leukocyte adhesion and migration to regulate the inflammatory response.[11] Following infection, CD11b+ is up-regulated, activating these immune responses, which then activate an increased expression of TSPO. These immune cells can cause myocarditis which can progress to dilated cardiomyopathy and heart failure.[11]

Apoptosis

Ligands of TSPO have been shown to induce apoptosis in human colorectal cancer cells. In lymphatic tissues, TSPO modulates apoptosis of thymocytes via reduction of mitochondrial transmembrane potential.[16]

Stress adaptation

TSPO in the basal land plant Physcomitrella patens, a moss, is essential for adaptation to salt stress.[17]

Tissue distribution

TSPO is found in many regions of the body including the human iris/ciliary-body.[18] Other tissues include the heart, liver, adrenal and testis, as well as hemopoietic and lymphatic cells.[19] "Peripheral" benzodiazepine receptors are also found in the brain, although only at around a quarter the expression levels of the "central" benzodiazepine receptors located at the plasma membrane.[20]

Therapeutic applications

TSPO has been shown to be involved in a number of processes such as inflammation,[12] [21] and TSPO ligands may be useful anti-cancer drugs.[22] [23]

Pharmacological activation of TSPO has been observed to be a potent stimulator of steroid biosynthesis[24] [25] including neuroactive steroids such as allopregnanolone in the brain, which exert anxiolytic properties.[26] Thus, TSPO ligands such as emapunil, alpidem, and etifoxine have been proposed to be useful as potential anxiolytics which may have less addiction-based side effects than traditional benzodiazepine-type drugs.,[27] [28] [29] [30] though toxicity side-effects remain a significant barrier in drug development.[31]

A 2013 study led by researchers from USC Davis School of Gerontology showed that TSPO ligands can prevent and at least partially correct abnormalities present in a mouse model of Alzheimer's disease.[32]

TSPO as a biomarker is a newly discovered non-invasive procedure, and has also been linked as a biomarker for other cardiovascular related diseases including: myocardial infarction (due to ischemic reperfusion), cardiac hypertrophy, atherosclerosis, arrhythmias, and large vessel vasculitis.[15] TSPO can be used as a biomarker to detect the presence and severity of inflammation in the heart and atherosclerotic plaques.[11] Inhibiting the over-production of TSPO can lead to a reduced incidence of arrhythmias which are most often caused by ischemia reperfusion injury.[15] TSPO ligands are used as a therapy after ischemia reperfusion injury to preserve the action potentials in cardiac tissue and restore normal electrical activity of the heart.[10] Higher levels of TSPO are present in those with heart disease, a change that is more common in men than women because testosterone worsens the inflammation causing permanent damage to the heart.[11]

The first high-resolution 3D solution structure of mammalian (mouse) translocator protein (TSPO) in a complex with its diagnostic PK11195 ligand was determined by means of NMR spectroscopy techniques by scientists from the Max-Planck Institute for Biophysical Chemistry in Goettingen in Germany in March 2014 (Jaremko et al., 2014) and has a PDB id: 2MGY. Obtained high-resolution clearly confirms a helical character of a protein and its complex with a diagnostic ligand in solution. The 3D structure of the mTSPO-PK11195 complex comprises five transmembrane α-helices (TM1 to TM5) that tightly pack together in the clockwise order TM1-TM2-TM5-TM4-TM3 (cytosol view). The mammalian TSPO in a complex with diagnostic ligand is nomomeric. The loop located in between TM1 and TM2 helices closes the entrance to the space between helices in which are bound with PK11195 molecule. Site-directed mutagenesis studies of mTSPO revealed that region important for PK11195 binding comprise amino acids from 41 to 51, because the deletion of this region resulted in the decrease in PK11195 binding (Fan et al., 2012).

The mammalian TSPO in a complex with the diagnostic ligand PK11195 is monomeric.[33] [34]

Imaging

Ligands of the TSPO are very useful for imaging of inflammation. For example, the radioligand [3H]PK-11195 has been used in receptor autoradiography to study neuroinflammation following brain injury. The affinity of [11C]PBR28 depends on a single polymorphism (rs6971) in the TSPO gene.[35]

Measuring microglial activation in vivo is possible using PET imaging and radioligands binding to 18 kDa translocator protein (TSPO).[36] Activation can be measured using the PET tracer (R)-[11C]PK11195 and others like PBR28 are under research.[37]

Ligands

TSPO ligands[1] (endogenous or synthetic) modulate the action of this receptor, activating the transport of cholesterol from the outer to the inner mitochondrial membrane.

Agonists

Peptides
Non-peptides

Antagonists

See also

Notes and References

  1. Mokrov GV, Deeva OA, Gudasheva TA . The Ligands of Translocator Protein: Design and Biological Properties . Current Pharmaceutical Design . 27 . 2 . 217–237 . 2021 . 32881658 . 10.2174/1381612826666200903122025 . 221498255 .
  2. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M . 6 . Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function . Trends in Pharmacological Sciences . 27 . 8 . 402–409 . August 2006 . 16822554 . 10.1016/j.tips.2006.06.005 .
  3. Chang YJ, McCabe RT, Rennert H, Budarf ML, Sayegh R, Emanuel BS, Skolnick P, Strauss JF . 6 . The human "peripheral-type" benzodiazepine receptor: regional mapping of the gene and characterization of the receptor expressed from cDNA . DNA and Cell Biology . 11 . 6 . 471–480 . 1992 . 1326278 . 10.1089/dna.1992.11.471 .
  4. Riond J, Mattei MG, Kaghad M, Dumont X, Guillemot JC, Le Fur G, Caput D, Ferrara P . 6 . Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor . European Journal of Biochemistry . 195 . 2 . 305–311 . January 1991 . 1847678 . 10.1111/j.1432-1033.1991.tb15707.x . free .
  5. Bogan RL, Davis TL, Niswender GD . Peripheral-type benzodiazepine receptor (PBR) aggregation and absence of steroidogenic acute regulatory protein (StAR)/PBR association in the mitochondrial membrane as determined by bioluminescence resonance energy transfer (BRET) . The Journal of Steroid Biochemistry and Molecular Biology . 104 . 1–2 . 61–67 . April 2007 . 17197174 . 10.1016/j.jsbmb.2006.10.007 . 24634653 .
  6. Casellas P, Galiegue S, Basile AS . Peripheral benzodiazepine receptors and mitochondrial function . Neurochemistry International . 40 . 6 . 475–486 . May 2002 . 11850104 . 10.1016/S0197-0186(01)00118-8 . 18428847 .
  7. Lacapère JJ, Papadopoulos V . Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis . Steroids . 68 . 7–8 . 569–585 . September 2003 . 12957662 . 10.1016/s0039-128x(03)00101-6 . 26232564 . bile acid .
  8. Morohaku K, Pelton SH, Daugherty DJ, Butler WR, Deng W, Selvaraj V . Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis . Endocrinology . 155 . 1 . 89–97 . January 2014 . 24174323 . 3868810 . 10.1210/en.2013-1556 .
  9. Midzak A, Papadopoulos V . Binding domain-driven intracellular trafficking of sterols for synthesis of steroid hormones, bile acids and oxysterols . Traffic . 15 . 9 . 895–914 . September 2014 . 24890942 . 10.1111/tra.12177 . free .
  10. Qi X, Xu J, Wang F, Xiao J . Translocator protein (18 kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseases . Oxidative Medicine and Cellular Longevity . 2012 . 162934 . 2012 . 23251719 . 3516045 . 10.1155/2012/162934 . free .
  11. Fairweather D, Coronado MJ, Garton AE, Dziedzic JL, Bucek A, Cooper LT, Brandt JE, Alikhan FS, Wang H, Endres CJ, Choi J, Pomper MG, Guilarte TR . 6 . Sex differences in translocator protein 18 kDa (TSPO) in the heart: implications for imaging myocardial inflammation . Journal of Cardiovascular Translational Research . 7 . 2 . 192–202 . March 2014 . 24402571 . 3951973 . 10.1007/s12265-013-9538-0 .
  12. Wolf A, Herb M, Schramm M, Langmann T . The TSPO-NOX1 axis controls phagocyte-triggered pathological angiogenesis in the eye . Nature Communications . 11 . 1 . 2709 . June 2020 . 32483169 . 7264151 . 10.1038/s41467-020-16400-8 . 2020NatCo..11.2709W . free .
  13. News: Pawlikowski M . Immunomodulating effects of peripherally acting benzodiazepines . Academic press . In Peripheral Benzodiazepine Receptors . New York . 125–135 . 1993 .
  14. Ren H, Han R, Chen X, Liu X, Wan J, Wang L, Yang X, Wang J . 6 . Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update . Journal of Cerebral Blood Flow and Metabolism . 40 . 9 . 1752–1768 . September 2020 . 32423330 . 7446569 . 10.1177/0271678X20923551 .
  15. Batarseh A, Papadopoulos V . Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states . Molecular and Cellular Endocrinology . 327 . 1–2 . 1–12 . October 2010 . 20600583 . 2922062 . 10.1016/j.mce.2010.06.013 .
  16. Tanimoto Y, Onishi Y, Sato Y, Kizaki H . Benzodiazepine receptor agonists modulate thymocyte apoptosis through reduction of the mitochondrial transmembrane potential . Japanese Journal of Pharmacology . 79 . 2 . 177–183 . February 1999 . 10202853 . 10.1254/jjp.79.177 . free .
  17. Frank W, Baar KM, Qudeimat E, Woriedh M, Alawady A, Ratnadewi D, Gremillon L, Grimm B, Reski R . 6 . A mitochondrial protein homologous to the mammalian peripheral-type benzodiazepine receptor is essential for stress adaptation in plants . The Plant Journal . 51 . 6 . 1004–1018 . September 2007 . 17651369 . 10.1111/j.1365-313X.2007.03198.x . free .
  18. Valtier D, Malgouris C, Gilbert JC, Guicheney P, Uzan A, Gueremy C, Le Fur G, Saraux H, Meyer P . 6 . Binding sites for a peripheral type benzodiazepine antagonist ([3H]PK 11195) in human iris . Neuropharmacology . 26 . 6 . 549–552 . June 1987 . 3037422 . 10.1016/0028-3908(87)90146-8 . 45035355 .
  19. Woods MJ, Williams DC . Multiple forms and locations for the peripheral-type benzodiazepine receptor . Biochemical Pharmacology . 52 . 12 . 1805–1814 . December 1996 . 8951338 . 10.1016/S0006-2952(96)00558-8 .
  20. Marangos PJ, Patel J, Boulenger JP, Clark-Rosenberg R . Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864 . Molecular Pharmacology . 22 . 1 . 26–32 . July 1982 . 6289073 .
  21. Chen MK, Guilarte TR . Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair . Pharmacology & Therapeutics . 118 . 1 . 1–17 . April 2008 . 18374421 . 2453598 . 10.1016/j.pharmthera.2007.12.004 .
  22. Santidrián AF, Cosialls AM, Coll-Mulet L, Iglesias-Serret D, de Frias M, González-Gironès DM, Campàs C, Domingo A, Pons G, Gil J . 6 . The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells . Haematologica . 92 . 12 . 1631–1638 . December 2007 . 18055986 . 10.3324/haematol.11194 . free . 2445/127632 . free .
  23. Kugler W, Veenman L, Shandalov Y, Leschiner S, Spanier I, Lakomek M, Gavish M . Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine . Cellular Oncology . 30 . 5 . 435–450 . 2008 . 18791274 . 4618834 . 10.3233/clo-2008-0431 .
  24. Veenman L, Papadopoulos V, Gavish M . Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response . Current Pharmaceutical Design . 13 . 23 . 2385–2405 . 2007 . 17692008 . 10.2174/138161207781368710 .
  25. Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G . 6 . Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands . Neuropharmacology . 53 . 2 . 318–329 . August 2007 . 17631921 . 10.1016/j.neuropharm.2007.05.016 . 39793765 .
  26. Farb DH, Ratner MH . Targeting the modulation of neural circuitry for the treatment of anxiety disorders . Pharmacological Reviews . 66 . 4 . 1002–1032 . October 2014 . 25237115 . 10.1124/pr.114.009126 . 14537740 .
  27. Mealy NE, Bayés M, Lupone B . 2006 . Psychiatric Disorders . Drugs of the Future . 31 . 3. 259 .
  28. Da Settimo F, Simorini F, Taliani S, La Motta C, Marini AM, Salerno S, Bellandi M, Novellino E, Greco G, Cosimelli B, Da Pozzo E, Costa B, Simola N, Morelli M, Martini C . 6 . Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis . Journal of Medicinal Chemistry . 51 . 18 . 5798–5806 . September 2008 . 18729350 . 10.1021/jm8003224 .
  29. Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C . Translocator protein ligands as promising therapeutic tools for anxiety disorders . Current Medicinal Chemistry . 16 . 26 . 3359–3380 . September 2009 . 19548867 . 10.2174/092986709789057653 .
  30. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F, Uzunov V, McAllister KH, Bertaina-Anglade V, La Rochelle CD, Tuerck D, Floesser A, Kiese B, Schumacher M, Landgraf R, Holsboer F, Kucher K . 6 . Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects . Science . 325 . 5939 . 490–493 . July 2009 . 19541954 . 10.1126/science.1175055 . 26125316 . 2009Sci...325..490R .
  31. Skolnick P . Anxioselective anxiolytics: on a quest for the Holy Grail . Trends in Pharmacological Sciences . 33 . 11 . 611–620 . November 2012 . 22981367 . 3482271 . 10.1016/j.tips.2012.08.003 .
  32. Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee JW, Melcangi RC, Pike CJ . Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease . The Journal of Neuroscience . 33 . 20 . 8891–8897 . May 2013 . 23678130 . 3733563 . 10.1523/JNEUROSCI.1350-13.2013 .
  33. Jaremko L, Jaremko M, Giller K, Becker S, Zweckstetter M . Structure of the mitochondrial translocator protein in complex with a diagnostic ligand . Science . 343 . 6177 . 1363–1366 . March 2014 . 24653034 . 5650047 . 10.1126/science.1248725 . 2014Sci...343.1363J .
  34. Fan J, Lindemann P, Feuilloley MG, Papadopoulos V . Structural and functional evolution of the translocator protein (18 kDa) . Current Molecular Medicine . 12 . 4 . 369–386 . May 2012 . 22364126 . 10.2174/156652412800163415 .
  35. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP . 6 . An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 . Journal of Cerebral Blood Flow and Metabolism . 32 . 1 . 1–5 . January 2012 . 22008728 . 3323305 . 10.1038/jcbfm.2011.147 .
  36. Airas L, Rissanen E, Tuisku J, Rinne J . Microglial Activation Correlates with Disease Progression in Multiple Sclerosis . April 2015 . Neurology . 86 . 16 Supplement P4 . 167 .
  37. Mirzaei N, Tang SP, Ashworth S, Coello C, Plisson C, Passchier J, Selvaraj V, Tyacke RJ, Nutt DJ, Sastre M . 6 . In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's disease . Glia . 64 . 6 . 993–1006 . June 2016 . 26959396 . 10.1002/glia.22978 . 25681298 .
  38. Pellow S, File SE . Behavioural actions of Ro 5-4864: a peripheral-type benzodiazepine? . Life Sciences . 35 . 3 . 229–240 . July 1984 . 6087055 . 10.1016/0024-3205(84)90106-1 .
  39. Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, Weizman A . Enigma of the peripheral benzodiazepine receptor . Pharmacological Reviews . 51 . 4 . 629–650 . December 1999 . 10581326 .
  40. Papadopoulos V, Amri H, Boujrad N, Cascio C, Culty M, Garnier M, Hardwick M, Li H, Vidic B, Brown AS, Reversa JL, Bernassau JM, Drieu K . 6 . Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis . Steroids . 62 . 1 . 21–28 . January 1997 . 9029710 . 10.1016/S0039-128X(96)00154-7 . 1977513 . free .
  41. Costa E, Auta J, Guidotti A, Korneyev A, Romeo E . The pharmacology of neurosteroidogenesis . The Journal of Steroid Biochemistry and Molecular Biology . 49 . 4–6 . 385–389 . June 1994 . 8043504 . 10.1016/0960-0760(94)90284-4 . 33492066 . free .
  42. Garnier M, Boujrad N, Ogwuegbu SO, Hudson JR, Papadopoulos V . The polypeptide diazepam-binding inhibitor and a higher affinity mitochondrial peripheral-type benzodiazepine receptor sustain constitutive steroidogenesis in the R2C Leydig tumor cell line . The Journal of Biological Chemistry . 269 . 35 . 22105–22112 . September 1994 . 8071335 . 10.1016/S0021-9258(17)31762-3 . free .
  43. Bormann J, Ferrero P, Guidotti A, Costa E . Neuropeptide modulation of GABA receptor C1- channels . Regulatory Peptides. Supplement . 4 . 33–38 . 1985 . 2414820 . 10.1016/0167-0115(85)90215-0 .
  44. Bordet T, Buisson B, Michaud M, Drouot C, Galéa P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, Lacapère JJ, Massaad C, Schumacher M, Steidl EM, Maux D, Delaage M, Henderson CE, Pruss RM . 6 . Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis . The Journal of Pharmacology and Experimental Therapeutics . 322 . 2 . 709–720 . August 2007 . 17496168 . 10.1124/jpet.107.123000 . 17271734 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Translocator protein".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.